Helicore Biopharma, Inc., is a clinic-ready multi-product biopharmaceutical company focused on the discovery and development of novel weight-loss therapeutics.

 

Helicore’s lead candidate, HCR-188, is a first-in-class biologic GIP antagonist with a differentiated mechanism of action advancing to the clinic in Q1’25 as a monotherapy and in combination with GLP-1 in induction and maintenance settings. Helicore closed its $65M Series A financing in January 2024 and expects to enter the clinic early 2025.